Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Nasdaq100 ETF (QQQ) Price & Performance

Boston Scientific CorporationTrade
Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Nasdaq100 ETF — how do they compare? Boston Scientific Corporation trades at $51.59 (market cap $74.19B), while Nasdaq100 ETF trades at $724.76. The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BSXQQQ
Market Cap
$74.19B
Sector
Health
52-Week High
$108.14$746.16
52-Week Low
$42.63$558.34
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

Nasdaq100 ETF

QQQ trades at $725.07, up 0.59% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro increasing its position by 2,685.7%. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend momentum. The Nasdaq-100 tracker benefits from tech sector strength and AI-driven market leadership.

QQQ's outlook remains positive given tech sector momentum and institutional accumulation. Key risks include concentration in mega-cap tech stocks and potential volatility from Fed policy shifts. The ETF's long-term performance record and current technical setup support continued upside potential, though investors should monitor overbought conditions and sector rotation risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on QQQ